There may be a “silver bullet” for Ebola, a family of hemorrhagic viruses, one of which has killed more than 11,000 people in West Africa in the past two years.

Researchers at Vanderbilt University and the National University of Singapore have determined the structure of a human monoclonal antibody which, in an animal model, strongly neutralizes a type of the potentially lethal dengue virus.

Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus.

During the past five years, Vanderbilt University Medical Center has become a leader in “personalized medicine,” the use of genomic information to individualize patient care.

Can an implanted electrical device like a cardiac pacemaker effectively treat inflammatory diseases like rheumatoid arthritis, including cases that have not responded to drug therapy?

Don’t panic over Ebola. But don’t ignore it, either. That was the take-home message for U.S. citizens from a “mini-hearing” held by U.S. Sen. Lamar Alexander, R-Tenn., at Vanderbilt University Medical Center on Wednesday with researchers and health officials from Vanderbilt and the State of Tennessee.

Vanderbilt University researchers have partnered with Mapp Biopharmaceutical Inc. to develop new human antibody therapies for people exposed to the deadly Ebola and Marburg viruses.